1. Sharihi R, Amirizadeh N, Oodi A, Azarkeivan A.
Distribution of red blood cell alloantibodies among
transfusion-dependent β-Thalassemia patients in
different population of Iran: Effect of ethnicity.
Hemoglobin 2020; 44(1): 31-36.
2. Hindawi S, Badawi M, Elfayoumi R, Elgemmezi T,
Al Hassani A, Raml M, et al. The value of transfusion
of phenotyped blood units for thalassemia and sickle
cell anemia patients at an academic center.
Transfusion 2020; 60: S15-S21.
3. Azarkeivan A, Ahmadi MH, Zolfaghari S, Shaiegan
M, Ferdowsi S, Rezaei N, et al. RBC
alloimmunization and double alloantibodies in
thalassemic patients. Hematology 2015; 20(4): 223-
227.
4. Golpayegany MR, Tohidi MR, Hookari S, Fouladi B.
Prevalence of Anti-Erythrocyte Alloantibodies and
Relevant Factors among the Patients with Thalassemia
Major in Kermanshah, Iran. Int J Pediatr 2020; 8(9):
12023-12030.
5. Al-Riyami AZ, Daar S. Transfusion in
Haemoglobinopathies: Review and recommendations
for local blood banks and transfusion services in
Oman. Sultan Qaboos Univ Med J 2018; 18(1): e3-
e12.
6. Davari K, Soltanpour MS. Study of alloimmunization
and autoimmunization in Iranian β-thalassemia major
patients. Asian J Transfus Sci 2016; 10: 88-92.
7. Christopher AT, Jeanne EH. Transfusion-related red
blood cell alloantibodies: induction and consequences.
Blood 2019; 133(17): 1821-30.
8. Yanaşık M, Beşışık SK, Karaman S, Tuğcu D,
Karakaş Z. Red blood cell alloantibodies in
thalassemia major patients: an analysis from Istanbul.
Leuk Res 2019; 85: S62.
9. Vitrano A, Musallam KM, Meloni A, Karimi M, Daar
S, Ricchi P, et al. Development of a Thalassemia
International Prognostic Scoring System (TIPSS).
Blood Cells Mol Dis 2022: 102710.
10. Franchini M, Forni GL, Marano G, Cruciani M,
Mengoli C, Pinto V, et al. Red blood cell alloimmunisation in transfusion-dependent
thalassaemia: a systematic review. Blood Transfus
2019; 17(1): 4-15.
11. Mollahoseini Foomani F, Sadeghian MH, Bagheri
S, Badiee Z, Bazargani R, et al. Frequency of Kell and
Rh alloantibodies in Iranian Thalassemia Patients in
Khorasan Razavi Province, Iran. Int J Hematol Oncol
Stem Cell Res 2023; 17(1): 4-8.
12. Singha K, Yamsri S, Chaibunruang A, Srivorakun
H, Sanchaisuriya K, Fucharoen G, et al. Diagnostic
value of fetal hemoglobin Bart's for evaluation of fetal
α-thalassemia syndromes: application to prenatal
characterization of fetal anemia caused by
undiagnosed α-hemoglobinopathy. Orphanet J Rare
Dis 2022; 17(1): 45.
13. Van Vliet ME, Kerkhoffs JH, Harteveld CL,
Houwink EJF. Hemoglobinopathy prevention in
primary care: a reflection of underdetection and
difficulties with accessibility of medical care, a
quantitative study. Eur J Hum Genet 2022; 30(7): 790-
4.
14. Ghasemi A, Abbasian S, Ghaffari K, Salmanpour Z.
Prevalence of Alloantibodies and Autoantibodies in
Transfusion Dependent Thalassemia Patients. IJBC
2016; 8(3): 80-85.
15. Sadeghian MH, Keramati MR, Badiei Z, Ravarian
M, Ayatollahi H, Rafatpanah H, et al.
Alloimmunization among transfusion-dependent
thalassemia patients. Asian J Transfus Sci. 2009; 3(2):
95-8.
16. Keikhaei B, Hirad Far A, Abolghasemi H,
Mousakhani H, Ghanavat M, Moghadam M, et al. Red
Blood Cell Alloimmunization in Patients with
Thalassemia Major and Intermediate in Southwest
Iran. Iranian Journal of Blood and Cancer 2013; 6: 41-
46.
17. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel
P, Vichinsky EP. Alloimmunization and erythrocyte
autoimmunization in transfusion-dependent
thalassemia patients of predominantly asian descent.
Blood 2000; 96(10): 3369-73.
18. El-Danasoury AS, Eissa DG, Abdo RM, Elalfy MS.
Red blood cell alloimmunization in transfusion-
dependent Egyptian patients with thalassemia in a
limited donor exposure program. Transfusion. 2012;
52(1): 43-47.
19. Ho HK, Ha SY, Lam CK, Chan GC, Lee TL, Chiang
AK, et al. Alloimmunization in Hong Kong southern
Chinese transfusion-dependent thalassemia patients.
Blood 2001; 97(12): 3999-4000.
20. Patel AS, Gamit S, Gohil M. Role of RBC’s
alloimmunization in multiple transfused thalassaemia
patients. Int J Res Med Sci 2016; 4: 822-828.
21. El-Beshlawy A, Salama AA, El-Masry MR, El
Husseiny NM, Abdelhameed AM. A study of red
blood cell alloimmunization and autoimmunization
among 200 multitransfused Egyptian β thalassemia
patients. Sci Rep 2020; 10(1): 21079.
22. Alves VM, Martins PR, Soares S, Araújo G,
Schmidt LC, Costa SS, et al. Alloimmunization
screening after transfusion of red blood cells in a
prospective study. Rev Bras Hematol Hemoter. 2012;
34(3): 206-211.
23. Makarovska-Bojadzieva T, Velkova E, Blagoevska
M. The Impact of Extended Typing On Red Blood
Cell Alloimmunization in Transfused Patients. Open
Access Maced J Med Sci 2017; 5(2): 107-11.
24. Tormey CA, Hendrickson JE. Transfusion-related
red blood cell alloantibodies: induction and
consequences. Blood 2019; 133(17): 1821-1830.
25. Sharma RR, Marwaha N. Leukoreduced blood
components: Advantages and strategies for its
implementation in developing countries. Asian J
Transfus Sci 2010; 4(1): 3-8.
26. Bilgin YM, van de Watering LM, Brand A. Clinical
effects of leucoreduction of blood transfusions. Neth J
Med 2011; 69(10): 441-50.
27. Koochakzadeh L, Kajiyazdi M, Khoshhal F,
Hashemi A, Khabazkhoob M. Prevalence of
Alloantibodies in Thalassemia Patients and Its
Relationship With Age, Gender and Blood Group.
Acta Med Iran 2023; 61(1): 52-56.